Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Drüeke, T. B.
Right arrow Articles by Locatelli, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drüeke, T. B.
Right arrow Articles by Locatelli, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2003) 18: 1982-1983
© 2003 European Renal Association-European Dialysis and Transplant Association

Editorial Comment

Stopping a medical research project for financial reasons

Tilman B. Drüeke1, Béatrice Descamps-Latscha1 and Francesco Locatelli2

1INSERM Unit 507 and Service de Néphrologie, Hôpital Necker, Paris, France and 2Department of Nephrology and Dialysis, Azienda Ospedale di Lecco, Ospedale A. Manzoni, Lecco, Italy

Correspondence and offprint requests to: Tilman B. Drüeke, MD, FRCP, Unité 507 de Inserm et Service de Néphrologie, Hôpital Necker, 161 rue de Sèvres, 75743 Paris Cedex 15, France. Email: drueke@necker.fr

Keywords: discontinuation; financial reasons; research project; stopping

The first 10% of the full text of this article appears below.

Recently, a multicentre clinical trial set up by nephrology groups in several countries in the European Union, under the instigation and with the active logistical support of the Zambon group in Italy, has been stopped at its very start, for undeclared reasons. In fact, the week before the first patients were to start their treatment protocol, the investigators were informed that the study was cancelled.

The purpose of the study was to examine possible beneficial effects of the antioxidant drug N-acetylcysteine (NAC), marketed by Zambon, on the anaemia of chronic haemodialysis patients. In particular, the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
C. Di Padova
Stopping a medical research project for financial reasons
Nephrol. Dial. Transplant., April 1, 2004; 19(4): 1015 - 1015.
[Full Text] [PDF]